Verrica Pharmaceuticals Inc. Common Stock (VRCA) Stock Price

VRCAStock

$4.94−10.89%52W

Market Cap$84.86M

P/E—

PEG Ratio—

Div yield—

Beta1.61

VRCA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-31.02%

Price vs S&P 500 (4W)-12.87%

VGM Score62.34

Book Value / Share (Quarterly)$0.93

P/TBV (Annual)3.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)57.94%

Cash Flow / Share (Quarterly)$-0.82

Price vs S&P 500 (YTD)-53.35%

Gross Margin (TTM)89.52%

Net Profit Margin (TTM)-47.97%

EPS (TTM)$-1.03

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-1.03

EPS (Annual)$-1.68

ROI (Annual)-69.35%

Gross Margin (Annual)90.33%

Net Profit Margin (5Y Avg)-586.69%

Cash / Share (Quarterly)$1.20

Revenue Growth QoQ (YoY)46.06%

ROA (Last FY)-37.95%

Revenue Growth TTM (YoY)417.63%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-141.89%

Operating Margin (TTM)-41.18%

Cash Flow / Share (Annual)$-1.03

P/B Ratio5.42x

P/B Ratio (Quarterly)5.66x

Net Income / Employee (Annual)$-235,300

EV / Revenue (TTM)1.81x

Net Interest Coverage (TTM)-3.29x

ROA (TTM)-42.97%

EPS Incl Extra (Annual)$-1.68

Current Ratio (Annual)2.59x

Quick Ratio (Quarterly)1.84x

3-Month Avg Trading Volume0.06M

52-Week Price Return-10.89%

Revenue / Employee (TTM)$489,000

Tangible BV / Share (Quarterly)$1.01

P/S Ratio (Annual)2.44x

Asset Turnover (Annual)0.75x

52-Week High$9.82

Operating Margin (5Y Avg)-540.49%

EPS Excl Extra (Annual)$-1.68

CapEx CAGR (5Y)-47.55%

Tangible BV CAGR (5Y)36.44%

26-Week Price Return-19.77%

Quick Ratio (Annual)2.28x

13-Week Price Return-17.46%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)2.10x

Enterprise Value$67.28M

Asset Turnover (TTM)0.90x

Book Value / Share Growth (5Y)-10.58%

Revenue / Employee (Annual)$468,100

Pretax Margin (Annual)-50.27%

Cash / Share (Annual)$1.75

3-Month Return Std Dev59.63%

Net Income / Employee (TTM)$-234,600

ROE (Last FY)-72.29%

Net Interest Coverage (Annual)-1.71x

EPS Basic Excl Extra (Annual)$-1.68

Receivables Turnover (TTM)5.58x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-1.03

ROI (TTM)-83.00%

P/S Ratio (TTM)2.34x

Pretax Margin (5Y Avg)-586.69%

Revenue / Share (Annual)$3.34

Tangible BV / Share (Annual)$0.97

Price vs S&P 500 (52W)-29.20%

Year-to-Date Return-41.40%

5-Day Price Return4.06%

EPS Normalized (Annual)$-1.68

ROA (5Y Avg)-72.01%

Net Profit Margin (Annual)-50.27%

Month-to-Date Return-6.71%

Cash Flow / Share (TTM)$-1.08

EBITD / Share (Annual)$-1.24

Operating Margin (Annual)-38.56%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-68.97%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.03

P/TBV (Quarterly)3.76x

P/B Ratio (Annual)3.19x

Inventory Turnover (TTM)1.76x

Pretax Margin (TTM)-47.97%

Book Value / Share (Annual)$1.44

Price vs S&P 500 (13W)-20.25%

Beta1.61x

Revenue / Share (TTM)$1.74

ROE (TTM)-87.04%

52-Week Low$3.28

vGradeB

gGradeA

mGradeC

vgmGradeB

VRCA Earnings Surprise History

Q2 250.25est. -0.83

Q3 250.13est. -0.84

Q4 25-0.51est. -0.64

Q2 26-0.48est. -0.47

VRCA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.09

4.08

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
VRCAVerrica Pharmaceuticals Inc. Common Stock	B	A	C	$4.94
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Verrica Pharmaceuticals Inc. Common Stock

Verrica Pharmaceuticals is a dermatology therapeutics company developing novel treatments for contagious viral skin diseases. Its lead product candidate, VP-102, targets molluscum contagiosum and common warts, addressing significant market opportunities in pediatric and adult populations.